Abstract
The effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B, and LCAT activity was investigated in 16 hyperlipidemic, non-insulin-dependent diabetics, who were treated for 8 weeks with either placebo or bezafibrate in a double-blind, cross-over design. Bezafibrate induced a significant decrease in plasma triglycerides ( P < 0.01), cholesterol ( P < 0.05), VLDL triglycerides ( P < 0.05) and VLDL cholesterol ( P < 0.01), and a significant increase in HDL cholesterol ( P < 0.01), whereas LDL cholesterol remained unchanged. The apolipoprotein AI/apolipoprotein B ratio increased significantly ( P < 0.05), although individual changes in these apolipoproteins were not significant. Apolipoprotein AII increased significantly ( P < 0.0001) and the apolipoprotein AI/apolipoprotein AII ratio decreased ( P < 0.0001), indicating an increase in the HDL 3 rather than the HDL 2 fraction. No significant change in LCAT activity was observed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
